{"url_path":"/sec/azta/8-k/2026-07-08/item-2-01","section_key":"item-2-01","section_title":"Item 2.01 Completion of Acquisition or Disposition of Assets.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-08","source_url":"https://www.sec.gov/Archives/edgar/data/933974/0001628280-26-047591-index.html","accession_number":"0001628280-26-047591","cik":"0000933974","ticker":"AZTA","issuer_name":"Azenta, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/933974/0001628280-26-047591-index.html","primary_entity_key":"0000933974","primary_entity_name":"Azenta, Inc."},"word_count":150,"has_tables":true,"body_markdown":"Item 2.01. Completion of Acquisition or Disposition of Assets.\n\nOn July 1, 2026, Azenta Germany GmbH, a wholly owned subsidiary of the Company, completed the sale of the entire issued share capital of B Medical Systems S.à r.l. (“B Medical”) to Thelema (the “Transaction”) pursuant to the Sale and Purchase Agreement. The aggregate purchase price for the Transaction was USD 63,000,000, consisting of USD 28,000,000 cash paid at or prior to closing and USD 35,000,000 funded through the Vendor Loan Agreement described in Item 1.01 above. The purchase price is fixed and not subject to customary post-closing adjustments.\n\nAs previously disclosed in the Company’s Current Report on Form 8-K filed on April 2, 2026, the Transaction did not close by March 31, 2026 due to Thelema’s inability at that time to secure the required financing. The Transaction was completed on July 1, 2026 following the satisfaction of the closing conditions."}